APA (7th ed.) Citation

LR, L. (2026). Long-term safety and efficacy of aficamten in the evolving era of myosin inhibition for obstructive hypertrophic cardiomyopathy. European heart journal, 47(24), 3132. https://doi.org/10.1093/eurheartj/ehag059

Chicago Style (17th ed.) Citation

LR, Lopes. "Long-term Safety and Efficacy of Aficamten in the Evolving Era of Myosin Inhibition for Obstructive Hypertrophic Cardiomyopathy." European Heart Journal 47, no. 24 (2026): 3132. https://doi.org/10.1093/eurheartj/ehag059.

MLA (9th ed.) Citation

LR, Lopes. "Long-term Safety and Efficacy of Aficamten in the Evolving Era of Myosin Inhibition for Obstructive Hypertrophic Cardiomyopathy." European Heart Journal, vol. 47, no. 24, 2026, p. 3132, https://doi.org/10.1093/eurheartj/ehag059.